Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Papillary Dermis

Papillary Dermis

Dermis
The dermis might be considered the "core" of the integumentary system, as distinct from the epidermis and hypodermis. It contains blood and lymph vessels, nerves, and other structures, such as hair follicles and sweat glands. The dermis is made of two layers of connective tissue that comprise an interconnected mesh of elastin and collagenous fibers, produced by fibroblasts.
Papillary Layer
The papillary layer is made of loose, areolar connective tissue, which means the collagen and...

Cells of the Epidermis

Cells of the Epidermis

The epidermis is made of four or five layers of epithelial cells, depending on its location in the body. From deep to superficial, these layers are the stratum basale, stratum spinosum, stratum granulosum, stratum lucidum, and stratum corneum.
The cells in all these layers except the stratum basale are called keratinocytes, a type of cell that manufactures and stores the protein keratin. The keratinocytes in the stratum corneum are dead and regularly slough away, being replaced by cells from...

Cancer Cell Migration through Invadopodia

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...

Cellular Adaptation IV: Dysplasia and Metaplasia

Cellular Adaptation IV: Dysplasia and Metaplasia

DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...

Clinical Applications of Epidermal Stem Cells

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF<sup>V600</sup> mutation-positive melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.

Drugs of today (Barcelona, Spain : 1998)·2021

Same author

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer<sup>☆</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.

ESMO open·2021

Search research articles

Related Experiment Video

Updated: May 20, 2026

Cell Population Analyses During Skin Carcinogenesis

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

Vismodegib in basal cell carcinoma.

R N Amaria¹, D W Bowles, K D Lewis

¹Cutaneous Malignancies and Developmental Therapeutics Programs, University of Colorado Cancer Center, Aurora, Colorado 80045, USA.

Drugs of Today (Barcelona, Spain : 1998)

|July 31, 2012

Summary

This summary is machine-generated.

Vismodegib effectively targets the hedgehog pathway, showing significant antitumor activity in preclinical and clinical studies for advanced basal cell carcinoma. This drug is now FDA-approved for treating unresectable or metastatic skin cancers.

More Related Videos

Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition

Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition

Published on: August 18, 2022

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments

Published on: August 8, 2025

Related Experiment Videos

Last Updated: May 20, 2026

Cell Population Analyses During Skin Carcinogenesis

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition

Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition

Published on: August 18, 2022

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments

Published on: August 8, 2025

Area of Science:

Oncology
Dermatology
Molecular Biology

Background:

Hedgehog signaling pathway activation is crucial in basal cell carcinoma (BCC) development.
Vismodegib is a novel small-molecule inhibitor targeting smoothened (SMO), a key component of this pathway.
Aberrant hedgehog signaling is implicated in various other tumor types.

Purpose of the Study:

To evaluate the efficacy and safety of vismodegib in preclinical models and clinical trials for BCC.
To establish vismodegib as a targeted therapy for advanced basal cell carcinomas.

Main Methods:

Preclinical studies in animal models assessing antitumor activity.
Phase I and II clinical trials in patients with advanced basal cell carcinomas.
FDA review and approval process for a novel cancer therapeutic.

Main Results:

Vismodegib demonstrated potent antitumor activity in hedgehog-dependent tumors, especially BCCs, in preclinical settings.
Clinical studies revealed dramatic anticancer responses in patients with advanced BCC.
FDA approval in January 2012 for specific indications.

Conclusions:

Vismodegib represents a significant advancement in targeted therapy for basal cell carcinoma.
The drug offers a new treatment option for patients with unresectable or metastatic BCC.
Targeting the hedgehog pathway is a validated strategy for treating certain skin cancers.